Seroatlas · Human Serome Atlas

ADRA2A

Alpha-2A adrenergic receptor

Also known as: ADA2A_HUMAN, ADRA2, ADRA2R, ADRAR

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P08913
Gene
ADRA2A
Ensembl
ENSG00000150594
Chromosome
10
Canonical length
465 aa
Protein class
FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters

OverviewNCBI Gene

Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. The alpha-2-adrenergic receptors are a type of adrenergic receptors (for adrenaline or epinephrine), which inhibit adenylate cyclase. These receptors include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. They are involved in regulating the release of neurotransmitter molecules from sympathetic nerves and from adrenergic neurons in the central nervous system. The sympathetic nervous system regulates cardiovascular function by activating adrenergic receptors in the heart, blood vessels and kidney. Studies in mouse revealed that both the alpha2A and alpha2C receptor subtypes were required for presynaptic transmitter release from the sympathetic nervous system in the heart and from central noradrenergic neurons. The alpha-2-adrenergic receptors are also involved in catecholamine signaling by extracellular regulated protein kinase 1 and 2 (ERK1/2) pathways. A clear association between the alpha-2-adrenergic receptor and disease has not been yet established. [provided by RefSeq, Sep 2019]

Canonical amino-acid sequenceUniProt

465 residues, UniProt reviewed canonical sequence.

>P08913|ADRA2A
     1  MFRQEQPLAE GSFAPMGSLQ PDAGNASWNG TEAPGGGARA TPYSLQVTLT LVCLAGLLML
    61  LTVFGNVLVI IAVFTSRALK APQNLFLVSL ASADILVATL VIPFSLANEV MGYWYFGKAW
   121  CEIYLALDVL FCTSSIVHLC AISLDRYWSI TQAIEYNLKR TPRRIKAIII TVWVISAVIS
   181  FPPLISIEKK GGGGGPQPAE PRCEINDQKW YVISSCIGSF FAPCLIMILV YVRIYQIAKR
   241  RTRVPPSRRG PDAVAAPPGG TERRPNGLGP ERSAGPGGAE AEPLPTQLNG APGEPAPAGP
   301  RDTDALDLEE SSSSDHAERP PGPRRPERGP RGKGKARASQ VKPGDSLPRR GPGATGIGTP
   361  AAGPGEERVG AAKASRWRGR QNREKRFTFV LAVVIGVFVV CWFPFFFTYT LTAVGCSVPR
   421  TLFKFFFWFG YCNSSLNPVI YTIFNHDFRR AFKKILCRGD RKRIV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADRA2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
7
Mean surface accessibility (rSASA)
0.46
Highest tissue expression
47 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 47 nTPM
  • cervix: 35 nTPM
  • breast: 31 nTPM
  • pancreas: 29 nTPM
  • vagina: 22 nTPM
  • gallbladder: 19 nTPM

Single-cell type

  • vascular smooth muscle cells: 157 nCPM
  • platelets: 119 nCPM
  • pancreatic duct cells: 75 nCPM
  • pericytes: 51 nCPM
  • cholangiocytes: 42 nCPM
  • endometrial glandular cells: 38 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • pons: 60 nTPM
  • choroid plexus: 20 nTPM
  • hypothalamus: 19 nTPM
  • medulla oblongata: 16 nTPM
  • white matter: 16 nTPM
  • midbrain: 15 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ADRA2A.

Disease | AllUniProt

Conditions ADRA2A is implicated in, by any mechanism.

  • Lipodystrophy, familial partial, 8 (FPLD8) MIM:620679

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 76 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Lipodystrophy, familial partial, type 8

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.23
gnomAD pLI
0
gnomAD missense Z
1.8
DepMap mean gene effect
0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ADRA2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ADRA2A as an antibody target. Whether an autoantibody or antibody against ADRA2A could matter depends on whether native ADRA2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ADRA2A is annotated at the cell surface, where native ADRA2A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ADRA2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ADRA2A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...